UK-based Heptares Therapeutic says it has achieved an important milestone in its immuno-oncology collaboration with AstraZeneca (LSE: AZN), which is focused on the development of AZD4635 (HTL-1071) as a potential new treatment for a range of cancers.
As a result, Heptares, a wholly owned subsidiary of Japan’s Sosei Group (TYO Mothers Index: 4565), has been notified today that the achievement has triggered a $12 million payment from AstraZeneca.
AZD4635 is a potent and selective, orally available, small molecule adenosine A2A receptor antagonist discovered by Heptares and licensed to AstraZeneca in 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze